Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630615 · ClinicalTrials.gov registry record
Circulating Tumor Cells (CTC) in Lung Cancer
A clinical trial of Lung Neoplasms, sponsored by Shadia Jalal.
- Recruiting
- Registry status
- 80
- Enrollment target
- 2
- Study locations
NCT02630615: Recruiting study of Lung Neoplasms, sponsored by Shadia Jalal.
NCT02630615 is a study of Lung Neoplasms that is actively recruiting participants, run by Shadia Jalal. The registered enrollment target is 80 participants, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02630615, a study of Lung Neoplasms, is actively recruiting participants, sponsored by Shadia Jalal.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
Primary Outcome
All analyses will be done by disease group (i.e., NSCLC and SCLC). For the primary objective, CTC derived xenografts will be generated, and CTCs will be analyzed for DNA repair defects, and used to evaluate the activity of novel DNA repair inhibitors. We will look at CTCs by group \[specific DNA defect (yes or no), treated vs untreated\] using histograms and compare groups statistically using two group Satterthwaite t-tests with a 0.050 two-sided significance level.
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (2)
Indiana
- Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
- Roudebush VA Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2026-10 |
What NCT02630615 shows while recruiting
NCT02630615 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 463-participant average among 22 other Lung Neoplasms trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Lung Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT02630615 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT02630615 about?
NCT02630615 is a clinical study titled "Circulating Tumor Cells (CTC) in Lung Cancer". The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
What is the current status of trial NCT02630615?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2017-10-19. Estimated completion is 2026-10.
What conditions does trial NCT02630615 study?
This clinical trial studies the following conditions: Lung Neoplasms.
What interventions are being tested in trial NCT02630615?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT02630615?
This trial is sponsored by Shadia Jalal, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02630615 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02630615's enrollment target sits among peer trials
80 12th of 22 higher than 11 of 22 other Lung Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
Specimen Banking From Patients With Lung Cancer
RECRUITING
-
TELESCOPE- TELEhealth Shared Decision-making COaching
RECRUITING · NA
-
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
RECRUITING · NA
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI